U.S. Transportation Stock News

Some AutoNation, Inc. ( NYSE:AN ) shareholders may be a little concerned to see that the Senior VP & Chief Accounting...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Last week, you might have seen that Chevron Corporation ( NYSE:CVX ) released its first-quarter result to the market...

Wintrust Financial Corporation ( NASDAQ:WTFC ) is about to trade ex-dividend in the next two days. The ex-dividend date...

A week ago, Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) came out with a strong set of quarterly numbers that could...

Shareholders in Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) may be thrilled to learn that the analysts have just...

Shareholders might have noticed that Nektar Therapeutics ( NASDAQ:NKTR ) filed its quarterly result this time last...

Unsurprisingly, Illumina, Inc.'s ( NASDAQ:ILMN ) stock price was strong on the back of its healthy earnings report. We...

A week ago, Callaway Golf Company ( NYSE:CALY ) came out with a strong set of quarterly numbers that could potentially...

Cencora, Inc. ( NYSE:COR ) is about to trade ex-dividend in the next three days. The ex-dividend date occurs one day...

Over the past year, insiders sold US$67k worth of Sypris Solutions, Inc. ( NASDAQ:SYPR ) stock at an average price of...

Some Bank of America Corporation ( NYSE:BAC ) shareholders may be a little concerned to see that insider Geoffrey...

In late April 2026, Marsh, a business of Marsh & McLennan Companies, announced a multi-year global partnership with Formula 1 as its first Official Risk Partner and Official Insurance Brokering Partner, alongside prominent trackside branding, curated race experiences, and a new content series on risk decision-making. Around the same time, Oliver Wyman, another Marsh & McLennan business, created senior AI-focused leadership roles to accelerate AI-enabled integration and transformation across...

uniQure (QURE) is in focus after first quarter results showed revenue of US$3.56 million and a net loss of US$53.54 million, alongside fresh regulatory progress for its Huntington’s disease gene therapy, AMT-130. See our latest analysis for uniQure. The stock has reacted strongly to the recent earnings update and regulatory progress on AMT-130, with a 1-month share price return of 79.84% and a 1-year total shareholder return of 110.34%, which may indicate building momentum rather than a...

Coty (COTY) is back in focus after recent earnings showed pressure on sales, wider losses, and withdrawn guidance, while a securities class action lawsuit adds a separate layer of uncertainty for shareholders. See our latest analysis for Coty. Recent selling pressure has been heavy, with the 1 year total shareholder return down 50.7% and the 3 year total shareholder return down 78.2%. At the same time, the 30 day share price return is up 13.82%, suggesting only a short term bounce after weak...

Martin Marietta Materials (MLM) has drawn attention after reporting first quarter 2026 sales of US$1,362 million and net income of US$1,513 million, alongside reaffirmed full year revenue and earnings guidance. See our latest analysis for Martin Marietta Materials. Despite the reaffirmed guidance and ongoing share repurchases, the stock has given up some ground in recent months, with the 90 day share price return down 16.63% even as the 5 year total shareholder return sits at 61.90%. This...

In early May 2026, Alcoa Corporation filed a US$506.08 million shelf registration for 8,000,000 common shares linked to its employee stock ownership plan and confirmed a quarterly dividend of US$0.10 per share payable on June 5, 2026. This combination of an employee-focused equity program and a maintained cash dividend underscores Alcoa’s parallel focus on workforce ownership and ongoing capital returns. With Wells Fargo’s upgrade reflecting increased confidence in Alcoa’s outlook, we’ll now...

In late April 2026, ResMed reported higher third‑quarter and nine‑month sales and earnings, confirmed a US$0.60 quarterly dividend, completed its long-running share repurchase program, and announced that long-serving CFO Brett Sandercock would retire in May 2026 while remaining an advisor through 2027. The appointment of former Exact Sciences finance chief Aaron Bloomer as ResMed’s new CFO brings extensive global healthcare finance and capital allocation experience that could influence how...

In the first quarter of 2026, Centuri Holdings reported revenue of US$723.17 million, up from US$550.08 million a year earlier, while reducing its net loss to US$9.53 million from US$17.94 million. Alongside this improvement, the company grew gross profit sharply, expanded its backlog to about US$6.50 billion, and reaffirmed its 2026 guidance while outlining multi-year growth targets. With revenue rising strongly and the backlog reaching about US$6.50 billion, we’ll now examine how this...

Waters (WAT) is back in focus after first quarter 2026 results beat expectations, aided by strong organic growth and the BD Biosciences and Diagnostic Solutions acquisitions, alongside higher full year 2026 financial guidance. See our latest analysis for Waters. Investors have responded quickly to the upgraded 2026 guidance, with the stock delivering a 17.64% 7 day share price return and an 8.60% 90 day share price return. However, year to date the share price return is down 7.02%, while the...

Recent news around Kopin (KOPN) centers on its partnership with Fabric.AI, including a MicroLED Neural I/o chip program for AI data centers, new development funding, and fresh leadership for this joint effort. See our latest analysis for Kopin. The recent news flow appears to have coincided with sharp share price momentum, with a 30 day share price return of 103.38% and a 90 day share price return of 130.21%. This has contributed to a very strong 1 year total shareholder return of 249.03% and...

In early May 2026, PTC Therapeutics reported first-quarter revenue of US$272.55 million versus US$1.18 billion a year earlier, swinging from net income of US$866.56 million to a net loss of US$2.81 million while still beating analyst expectations on both revenue and earnings per share. The company also released positive 24-month interim data for Huntington’s disease therapy votoplam and raised its 2026 product revenue guidance, underscoring how a strong Sephience launch and advancing...

Novavax (NVAX) recently reported first quarter 2026 results that beat revenue and loss expectations, helped by a US$30 million upfront payment from a new Pfizer licensing deal and fresh Matrix M partnership activity. See our latest analysis for Novavax. The stock has rallied strongly in recent months, with a 7 day share price return of 16.5% and a year to date share price return of 29.5%, although the 5 year total shareholder return remains down 92.4%. If you are looking beyond vaccines and...

Wendy's (WEN) stock is in focus after first quarter 2026 results topped market expectations on revenue and adjusted earnings, while management reaffirmed full year guidance and confirmed a quarterly dividend alongside a new China expansion agreement. See our latest analysis for Wendy's. The latest results and China expansion plan sparked a 1 day share price return of 4.51% to US$6.95, but the share price is still down 14.93% year to date and the 1 year total shareholder return is down 39.06%,...